Surveillance of adverse effects during a vaccination campaign against meningitis C

European Journal of Clinical Pharmacology

Volumn 61, Issue 12, 2005, Pages 907-911

  Laribière, Anne ^a   Miremont Salamé, Ghada ^a   Reyre, Hadrien ^a   Abouelfath, Abdelilah ^a   Liège, Ludovic ^a   Moore, Nicholas ^a   Haramburu, Françoise ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Adverse effects; Meningococcal vaccines; Pharmacovigilance; Postmarketing; Product surveillance

Indexed keywords

MENINGITIS VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGITATION; APPLICATION SITE DISCOMFORT; ARTHRITIS; ARTICLE; ASTHENIA; ASTHMA; BACKACHE; BRONCHOSPASM; CELLULITIS; CHILD; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG SURVEILLANCE PROGRAM; ECZEMA; FACE EDEMA; FACIAL NERVE PARALYSIS; FEBRILE CONVULSION; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING LOSS; HUMAN; INCIDENCE; INFANT; INFECTION; INJECTION SITE REACTION; INSOMNIA; LIPOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MASS IMMUNIZATION; MENINGISM; MENINGITIS; MIGRAINE; MULTIPLE SCLEROSIS; MUSCLE STIFFNESS; MYALGIA; NECK PAIN; NERVOUSNESS; NEURALGIA; OPEN STUDY; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURPURA; RASH; RESPIRATORY DISTRESS; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SKIN DISEASE; SYNCOPE; TONIC CLONIC SEIZURE; TURNER SYNDROME; URTICARIA; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; HUMANS; INFANT; MALE; MASS IMMUNIZATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES;

EID: 29144533819     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0053-3     Document Type: Article

References (21)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM (2001) Meningococcal disease. N Engl J Med 344:1378-88
2. Bonmarin I, Lévy-Bruhl D, Desenclos JC (2002) Infections invasives à méningocoques dans le Sud-Ouest de la France. Situation au 08/10/02. http://www.invs.sante.fr/surveillance/iim/ (accessed 13 June 2005)
3. Institut de Veille Sanitaire (2002) Analyse des cas d'infections invasives à méningocoque survenues en France depuis 1985. Evolution de l'incidence. Part relative des méningocoques de sérogroupe C. Septembre 2002. http://www.invs.sante.fr/communication/ index-ps.htm (accessed 13 June 2005)
4. Direction Générale de la Santé (2002) Avis du Conseil supérieur d'hygiène publique de France du 7 octobre 2002. http://www. sante.gouv.fr/htm/pointsur/infections/avis021007.htm (accessed 18 January 2005)
5. Lévy-Bruhl D, Perrocheau A, Mora M, Taha MK, Dromell-Chabrier S, Beytout J, Quatresous I (2002) Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dôme (France). Euro Surveill 7:74-76
6. Décret no°2004-99 du 29 janvier 2004 relatif à la pharmacovigilance et modifiant le code de la santé publique (deuxième partie: Décrets en Conseil d'Etat). Journal Officiel du 31 janvier 2004. http://www.legifrance.gouv.fr/WAspad/RechercheSimple-Texte.jsp (accessed 13 June 2005)
7. WHO adverse reaction terminology. WHO Collaborating Centre for International Drug Monitoring, Uppsala
8. Anatomical therapeutic chemical classification (ATC). WHO Collaborating Centre for Drug Statistics Methodology, Oslo
9. Bégaud B, Evreux JC, Jouglard J, Lagier G (1985) Unexpected or toxic drug reaction assessment (imputation). Therapie 40: 111-118
10. Charron M, Hemery C. Etude de la couverture vaccinale suite à la campagne de vaccination contre le méningocoque C dans les Landes, les Pyrénées Atlantiques et les Hautes Pyrénées en 2002. http://www.invs.sante.fr/surveillance/iim/ (accessed 13 June 2005)
11. Hood DA, Edwards IR (1989) Meningococcal vaccine: do some children experienced side effects? N Z Med J 102:65-7
12. Ball R, Braun MM, Mootrey GT (2001) Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clin Infect Dis 32:1273-80
13. Miller E, Slisbury D, Ramsay M (2002) Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20:S58-S67
14. Report of the Committee on Safety of Medicines Expert Working Group on Meningococcal Group C Conjugate Vaccines. Final report-21 May 2002. medicines.mhra.gov.uk/aboutagency/regframework/csm/csmhome.htm (accessed 13 June 2005)
15. Anonymous (2000) Safety of meningococcal group C conjugate vaccines. Curr Probl Pharmacovigilance 26:14
16. Ranganathan SS, Houghton JE, Davies DP, Routledge PA (2003) The involvement of nurses in reporting suspected adverse drug reactions: experience with the meningococcal vaccination scheme. Br J Clin Pharmacol 56:658-63
17. Salleras L, Dominguez A, Cardenosa N (2003) Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain. Vaccine 21:725-8
18. Anonymous (2003) Meningococcal vaccine: early experience is reassuring. Aust Adv Drug React Bull 22:22
19. Conseil supérieur d'hygiène publique de France (2003) Calendrier vaccinal 2003. Avis du Conseil supérieur d'hygiène publique de France, 17 janvier 2003. BEH 6:33-40
20. Bagheri H, Gony M, Montastruc JL (2005) Meningococcal serogroup C vaccine: a pharmacovigilance point of view. Therapie 60:287-294
21. De Wals P, Deceuninck G, Boulianne N, De Serres G (2004) Effectiveness of a mass immunization campaign using sero-group C meningococcal conjugate vaccine. JAMA 292:2491-4